Literature DB >> 17188039

LXIII Edward Jackson Memorial Lecture: Eye care: dollars and sense.

Hugh R Taylor1.   

Abstract

PURPOSE: The development of health economic data for vision loss and eye disease is described.
DESIGN: Data from population-based epidemiologic studies of eye disease, studies of the impact of vision loss on daily living, Australian national health-care costs, census, and demographic projections were combined to develop a model of the economic impact of vision loss in Australia.
METHODS: Data were considered to assess the current magnitude and costs of vision loss and to make projections as to future costs. Further analysis investigated the costs and economic benefits of various interventions to address avoidable vision loss.
RESULTS: The amount of vision loss increases three-fold and the number with vision loss will double in 20 years. Vision loss cost Australia a total of AU $9.85 billion in 2004. Vision loss ranks seventh in causes of loss of well-being. An intervention package to address avoidable vision loss would cost AU $190 million or AU $5,591/Quality Adjusted Life Year (QALY) and give lifetime savings of AU $911 million.
CONCLUSIONS: Although specific for Australia, these data can help guide health care policy debate and the priority given to eye care in other developed economies. For each dollar spent on the prevention of vision loss and eye care, there is a 5 dollar return to the community.

Entities:  

Mesh:

Year:  2006        PMID: 17188039     DOI: 10.1016/j.ajo.2006.10.003

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Convincing governments to act: VISION 2020 and the Millennium Development Goals.

Authors:  Hannah Faal; Clare Gilbert
Journal:  Community Eye Health       Date:  2007-12

2.  Tips and pitfalls in 23-gauge vitrectomy surgery: does one size fits (almost) all?

Authors:  Andrea Grosso; Claudio Panico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-31       Impact factor: 3.117

3.  Comparing the Impact of Refractive and Nonrefractive Vision Loss on Functioning and Disability: The Salisbury Eye Evaluation.

Authors:  Nazlee Zebardast; Bonnielin K Swenor; Suzanne W van Landingham; Robert W Massof; Beatriz Munoz; Sheila K West; Pradeep Y Ramulu
Journal:  Ophthalmology       Date:  2015-03-24       Impact factor: 12.079

4.  Twenty-five-gauge vitrectomy versus 23-gauge vitrectomy in the management of macular diseases: a comparative analysis through a Health Technology Assessment model.

Authors:  Andrea Grosso; Lorena Charrier; Emanuela Lovato; Claudio Panico; Cesare Mariotti; Giancarlo Dapavo; Roberto Chiuminatto; Roberta Siliquini; Maria Michela Gianino
Journal:  Int Ophthalmol       Date:  2013-09-07       Impact factor: 2.031

Review 5.  Challenges of ophthalmic care in the developing world.

Authors:  Alfred Sommer; Hugh R Taylor; Thulasiraj D Ravilla; Sheila West; Thomas M Lietman; Jeremy D Keenan; Michael F Chiang; Alan L Robin; Richard P Mills
Journal:  JAMA Ophthalmol       Date:  2014-05       Impact factor: 7.389

6.  The Frequency and Causes of Blindness in a Rural Region of Central Anatolia of Turkey.

Authors:  Enver Mirza; Gunsu Deniz Mirza; Refik Oltulu; Mehmet Okka; Ahmet Ozkagnici
Journal:  Eurasian J Med       Date:  2019-10

7.  Protocol: Effect of intravitreal bevacizumab (avastin) in the treatment of macular edema: A systematic review of randomized controlled trials.

Authors:  Hammad A Qazi
Journal:  J Res Med Sci       Date:  2012-12       Impact factor: 1.852

8.  The Causes and Frequency of Monocular and Binocular Blindness in Adults Applying to the Health Committee of a University Hospital in Central Anatolia

Authors:  Günsu Deniz Mirza; Mehmet Okka; Enver Mirza; Selman Belviranlı
Journal:  Turk J Ophthalmol       Date:  2021-10-26

9.  The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients.

Authors:  Anil Vaidya; Elio Borgonovi; Rod S Taylor; José-Alain Sahel; Stanislao Rizzo; Paulo Eduardo Stanga; Amit Kukreja; Peter Walter
Journal:  BMC Ophthalmol       Date:  2014-04-14       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.